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Background: In the phase III MPACT trial, nab-paclitaxel plus gemcitabine (nab-P + Gem) demonstrated superior efﬁcacy
versus Gem alone for patients with metastatic pancreatic cancer. We sought to examine the feasibility of positron emission
tomography (PET) and to compare metabolic response rates and associated correlations with efﬁcacy in the MPACT trial.
Patients and methods: Patients with previously untreated metastatic adenocarcinoma of the pancreas were randomized
1:1 to receive nab-P +Gem or Gem alone. Treatment continued until disease progression by RECIST or unacceptable toxicity.
Results: PET scans were carried out on the ﬁrst 257 patients enrolled at PET-equipped centers (PET cohort). Most patients
(252 of 257) had ≥2 PET-avid lesions, and median maximum standardized uptake values at baseline were 4.6 and 4.5 in the
nab-P +Gem and Gem-alone arms, respectively. In a pooled treatment arm analysis, a metabolic response by PET (best re-
sponse at any time during study) was associated with longer overall survival (OS) (median 11.3 versus 6.9 months; HR, 0.56;
P< 0.001). Efﬁcacy results within each treatment arm appeared better for patients with a metabolic response. The metabolic
response rate (best response and week 8 response) was higher for nab-P +Gem (best response: 72% versus 53%,
P= 0.002; week 8: 67% versus 51%; P= 0.014). Efﬁcacy in the PET cohort was greater for nab-P +Gem versus Gem alone,
including for OS (median 10.5 versus 8.4 months; hazard ratio [HR], 0.71; P = 0.009) and ORR by RECIST (31% versus 11%;
P< 0.001).
Conclusion: Pancreatic lesions were PET avid at baseline, and the rate of metabolic response was signiﬁcantly higher for
nab-P +Gem versus Gem alone at week 8 and for best response during study. Having a metabolic response was associated
with longer survival, and more patients experienced a metabolic response than a RECIST-deﬁned response.
ClinicalTrials.gov:NCT00844649.
Key words: pancreatic cancer, positron emission tomography, nab-paclitaxel, gemcitabine, metabolic response
introduction
Pancreatic cancer bears an extremely poor prognosis as evidenced
by the only 20% of patients who survive ≥1 year after diagnosis [1].
Thus, it is crucial to identify early markers of treatment efﬁcacy.
Positron emission tomography (PET) imaging, a technique that
uses radioactively labeled glucose 18F-ﬂuorodeoxyglucose (18F-
FDG), has been used for the study of cancer, as both a diagnostic
tool and, increasingly, as a measure of tumor response to treatment
[2–8]. Compared with conventional radiographic means of gauging
tumor response based on diameter, metabolic response by PET
may represent a more functional measure of tumor response or pro-
gression by directly assessing the degree of metabolic activity [6, 9].
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Tumor response measured by computed tomography (CT)
scan has been shown to predict patient survival in metastatic
solid tumors [10], and PET may serve as a complement or
improvement in this regard or as a surrogate modality if CT is
contraindicated. For example, a change from baseline in the
tumor uptake of 18F-FDG during treatment may be a predictive
marker of survival in gastric cancer [11]. Although PET imaging
has been validated as a marker of therapeutic efﬁcacy in some
cancers, such as lymphoma, gastrointestinal stromal tumors,
gastric cancer, colorectal cancer, non-small-cell lung cancer,
and melanoma [3, 4, 11–14], the potential of PET as a marker
of efﬁcacy in pancreatic cancer is still under investigation.
However, recent results conﬁrm that pancreatic lesions do take
up 18F-FDG (i.e. PET-avid) and can be imaged using PET
technology [15].
The correlation between metabolic response and efﬁcacy was
evaluated in a phase I/II trial in which patients with metastatic
pancreatic cancer were treated with nab-paclitaxel (nab-P) plus
gemcitabine (Gem) [16]. Patients who were treated at the
maximum tolerated dose of 125 mg/m2 (n = 44) demonstrated
an overall response rate [ORR; by Response Evaluation Criteria
In Solid Tumors (RECIST) version 1.0] of 48% and a median
overall survival (OS) of 12.2 months [16]. All patients had a
metabolic response by PET as deﬁned by the European
Organisation for Research and Treatment of Cancer (EORTC;
deﬁned in methods of this report) [16]. Patients who experi-
enced a complete metabolic response (31%) had a signiﬁcantly
longer OS compared with patients who experienced an incom-
plete metabolic response (median 20.1 versus 10.3 months;
P = 0.01).
The promising efﬁcacy results from the phase I/II trial led to a
large phase III trial (MPACT; N = 861), which demonstrated su-
perior efﬁcacy for nab-P + Gem versus Gem alone for all efﬁcacy
end points including OS [median: 8.7 versus 6.6 months; hazard
ratio (HR), 0.72; 95% conﬁdence interval (CI) 0.62–0.83;
P < 0.001] and independently assessed ORR (23% versus 7%;
P < 0.001) [17, 18]. Evaluation of tumor response by PET was
included as an exploratory objective in the MPACT protocol
based on the positive ﬁndings from the phase I/II trial described
above.
patients andmethods
The study design was described previously [18].
patients
Patients were required to have measurable (RECIST version 1.0) metastatic
adenocarcinoma of the pancreas. Additional eligibility criteria included a
Karnofsky performance status (KPS) ≥70 and bilirubin ≤upper limit of
normal. Prior chemotherapy in the adjuvant [except 5-ﬂuorouracil or Gem
as a radiation sensitizer] or metastatic setting was not allowed.
study design
Patients were randomized 1:1 (stratiﬁed by KPS, presence of liver metastases,
and geographic region) to receive nab-P 125 mg/m2 plus Gem 1000 mg/m2
on days 1, 8, and 15 every 28 days for 56 days or Gem alone 1000 mg/m2 on
days 1, 8, 15, 22, 29, 36, and 43 every 56 days (cycle 1) and then on days 1, 8,
and 15 every 28 days (cycle ≥2). Treatment continued until disease progres-
sion by RECIST or unacceptable toxicity.
patient population
All patients who had a baseline PET measurement were included in the PET
cohort. Some analyses were based on metabolic response at week 8 or 16 or
best response during study.
assessments
Tumor response was evaluated every 8 weeks by spiral CT or magnetic
resonance imaging (MRI) and graded according to RECIST version 1.0.
PET/CT scans were carried out in a cohort of the ﬁrst-enrolled patients at
PET-equipped cancer centers at baseline, week 8, and week 16 (68 patients
underwent PET imaging beyond week 16), and evaluated according to
EORTC criteria [6]. A complete metabolic response was deﬁned as complete
resolution of 18F-FDG uptake; a partial metabolic response was deﬁned as a
reduction in 18F-FDG standardized uptake value (SUV) ≥15%–25% after 1
cycle of treatment or >25% after ≥2 cycles of treatment. Additional descrip-
tion of PET imaging, as well as the imaging charter for the MPACT study
(supplementary Material S1, available at Annals of Oncology online),
includes detailed information on imaging by CT, MRI, and PET.
Treatment-related adverse events were graded according to the
National Cancer Institute Common Terminology Criteria for Adverse
Events, version 3.0.
results
characteristics of the PET cohort
PET/CT scans were carried out in 79 study sites in 257 patients
at baseline (1–8 patients per center; 165 in North America, 49 in
Australia, and 43 in Eastern Europe), 248 at week 8, and 162 at
week 16 (Figure 1). Baseline characteristics between the two
treatment arms were balanced within the PET cohort and
similar to the intent-to-treat (ITT) population (supplementary
Table S1, available at Annals of Oncology online). Forty-ﬁve
percent of patients were 65 years of age or older, two thirds of
patients had a KPS of 90 or 100, and 41% of patients had ≥3
sites of metastasis (identiﬁed by radiologic imaging). Within the
PET cohort, the rates of secondary therapy for patients whose
disease progressed during treatment were 52% for nab-P + Gem
and 56% for Gem alone. At baseline, 74% of patients had ≥3
PET-avid tumors [(primary or metastatic) median, 5.0 lesions
per patient in each treatment arm]. The baseline median
maximum SUV (SUVmax) was 4.6 for the nab-P + Gem arm
and 4.5 for the Gem-alone arm (mean ± standard deviation:
4.8 ± 1.9 for nab-P + Gem and 5.2 ± 2.9 for Gem alone).
efﬁcacy analyses based on best PET response
throughout study
In a pooled analysis of both treatment arms, patients with a
metabolic response [complete (CMR) or partial (PMR)] at any
time during the study had a signiﬁcantly longer OS than
patients without one (median 11.3 versus 6.9 months; HR 0.56;
95% CI 0.42–0.74; P < 0.001). Note that analyses throughout
this report are based on grouping CMR and PMR because of the
small number of patients with a CMR [11/130 (8%) in the nab-
P + Gem arm and 3/127 (2%) in the Gem arm]. In the nab-
P + Gem arm, ORR by RECIST was signiﬁcantly better for
patients who experienced a metabolic response compared with
patients who did not; the effects on progression-free survival
(PFS) and OS did not reach statistical signiﬁcance (P = 0.110
and 0.464, respectively; Table 1). The association of metabolic
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response with efﬁcacy was similar for the Gem-alone arm with
signiﬁcant differences observed for ORR, PFS, and OS (Table 1).
Kaplan–Meier curves of survival within each treatment arm
based on metabolic response are shown in Figure 2.
landmark efﬁcacy analyses based on PET response
at week 8 or 16
In a week-8 pooled analysis of the PET cohort, the metabolic re-
sponse rate was 60% (146/245), whereas the ORR by RECIST
(measured by CT) was 11% (27/245). Of the 146 patients with a
metabolic response by PET, 14% had an objective response, 81%
had stable disease, and 5% had progressive disease by RECIST
(Table 2). The longest median OS was observed in patients
(n = 20) with both a metabolic response and an objective re-
sponse by RECIST (13.5 months; Table 3). However, the
median OS for the 126 patients with a metabolic response in the
absence of a response by RECIST was >3 months longer than in
patients with neither type of tumor response (n = 92; 10.2 versus
6.9 months, respectively). The small set of patients (n = 7) who
ITT population
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No wk 8 or 16 scan 1 No wk 8 or 16 scan 2
Figure 1. Flow diagram of patients who received PET scans. Gem, gemcitabine; ITT, intent-to-treat; nab-P, nab-paclitaxel; PET, positron emission tomography.
Table 1. Efficacy as a function of best PET response
Efficacy nab-P + Gem Gem
PET response RRR or HRa
(95% CI)
P value PET response RRR or HRa
(95% CI)
P value
Yes (N = 93) No (N = 37) Yes (N = 67) No (N = 60)
ORR by RECIST 37% 16% 2.3 (1.03–4.92) 0.023 18% 3% 5.4 (1.25–23.04) 0.009
Median PFS 7.5 months 5.3 months 0.63 (0.36–1.11) 0.110 5.6 months 3.6 months 0.39 (0.24–0.66) <0.001
Median OS 11.5 months 8.0 months 0.85 (0.54–1.32) 0.464 10.9 months 6.3 months 0.43 (0.29–0.65) <0.001
aRRR =ORRPET response/ORRno PET response; HR =HRPET response/no PET response.
Gem, gemcitabine; HR, hazard ratio; nab-P, nab-paclitaxel; ORR, overall response rate; OS, overall survival; PET, positron emission tomography; PFS,
progression-free survival; RECIST, Response Evaluation Criteria In Solid Tumors; RRR, response rate ratio.
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did not experience a metabolic response by PET but did have a
response by RECIST had a median OS of 10.4 months.
At week 8, 86 of 129 patients (67%) in the nab-P + Gem arm
had a metabolic response versus 61 of 119 patients (51%) in the
Gem-alone arm (P = 0.014). A pooled analysis revealed that
patients with a metabolic response at week 8 had a signiﬁcantly
longer OS than those without a metabolic response at week 8
(median 10.5 versus 7.3 months; HR 0.68; 95% CI 0.51–0.91;
P = 0.008). Patients with a metabolic response also appeared to
have longer OS than patients without a metabolic response
within each treatment arm (supplementary Table S2, available
at Annals of Oncology online).
At week 16, 54 of 88 patients (61%) in the nab-P + Gem arm
had a metabolic response versus 26 of 74 patients (35%) in the
Gem-alone arm (P < 0.001). OS beneﬁts were also revealed for
patients with a metabolic response versus those without one at
week 16 in the pooled group (median 14.2 versus 9.2 months;
HR 0.55; 95% CI 0.39–0.78; P < 0.001) and within treatment
arms (supplementary Table S2, available at Annals of Oncology
online).
Findings for PFS and ORR at weeks 8 and 16 based on PET
response were consistent with OS ﬁndings (supplementary
Tables S2–S4, available at Annals of Oncology online).
results by treatment arm in the PET cohort
The median percent reductions in SUVmax from baseline at weeks
8 and 16 were both greater for nab-P + Gem versus Gem alone
(39.7% versus 27.6% and 44.1% versus 23.2%, respectively; sup-
plementary Table S5, available at Annals of Oncology online).
These reductions translated to signiﬁcantly higher metabolic re-
sponse rates for nab-P + Gem versus Gem alone (best response
during study: 72% versus 53%, P = 0.002; week 8: 67% versus
51%, P = 0.014; week 16: 61% versus 35%; P < 0.001).
The median follow-up times in the PET cohort for nab-P +Gem
and Gem-alone arms were 9.2 and 9.1 months, respectively, for
PFS and 28.6 and 26.2 months for OS. nab-P +Gem demonstrated
a higher ORR (31% versus 11%; response rate ratio, 2.79; 95% CI
1.60–4.87; P < 0.001) and longer PFS (median, 6.7 versus 4.3
months; HR, 0.62; 95% CI 0.44–0.86; P = 0.004) and OS (median,
Table 2. Tumor response by RECIST versus metabolic response by PET at week 8: pooled treatment arm analysis
Outcome CMR or PMR by PET (N = 146) SD by PET (N = 24) PD by PET (N = 66) PET response unevaluable (N = 9)
CR or PR by RECIST, n (%) 20 (8) 1 (<1) 5 (2) 1 (<1)
SD by RECIST, n (%) 118 (48) 21 (9) 48 (20) 6 (2)
PD by RECIST, n (%) 8 (3) 2 (<1) 12 (5) 2 (<1)
RECIST response unevaluable, n (%) 0 0 1 (<1) 0
CR, complete response; CMR, complete metabolic response; PD, progressive disease; PET, positron emission tomography; PMR, partial metabolic
response; PR, partial response; RECIST, Response Evaluation Criteria In Solid Tumors; SD, stable disease.
Table 3. Survival as a function of RECIST and PET response at
week 8
Complete or partial response by
RECIST
Yes No
N Median OS
(months)
N Median OS
(months)
Complete or partial MR Yes 20 13.5 126 10.2
No 7 10.4 92 6.9
MR, metabolic response; OS, overall survival; RECIST, Response
Evaluation Criteria In Solid Tumors.
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 3 6 9 12 15 18
Months
Patients at risk:
nab-P + Gem, MR:
nab-P + Gem, NMR:
Gem, NMR:
Gem, MR:
Pr
op
or
tio
n 
of
 o
ve
ra
ll s
ur
viv
al
21 24 27 30 33 36 39
Log-rank P < 0.001
nab-P + Gem, MR
nab-P + Gem, NMR
Gem, NMR
Gem, MR
93 92 78 62 45 30 20 15 11 6 3 1 1 0
67 66 53 39 28 21 17 12 5 3 1 0 0 0
37 32 24 15 13 9 7 7 5 3 1 0 0 0
60 56 32 17 9 4 2 1 1 0 0 0 0 0
Figure 2. Overall survival in each treatment arm based on metabolic response. Gem, gemcitabine; MR, metabolic response; nab-P, nab-paclitaxel; NMR, no
metabolic response.
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10.5 versus 8.4 months; HR, 0.71; 95% CI 0.54–0.92; P = 0.004)
versus Gem alone in the PET cohort. No new safety signals were
observed in the PET cohort.
discussion
To our knowledge, this is the largest cohort of patients (n = 257)
with pancreatic cancer to be evaluated by PET in a single
prospective trial. The median SUVmax (4.6 and 4.5 in the nab-
P + Gem and Gem-alone arms, respectively) and high percentage
of patients with ≥3 PET-avid lesions at baseline (74%) demon-
strate that PET imaging is feasible for response evaluation in
patients with metastatic pancreatic cancer. Furthermore, metabolic
response was associated with longer survival regardless of treat-
ment, and the rate of metabolic response by PET was signiﬁcantly
higher for patients who received nab-P + Gem versus Gem alone:
∼30% more patients achieved a metabolic response at any time
during the study (similar difference at week 8), and twice as many
patients had a metabolic response at week 16. In addition, the
treatment difference favoring nab-P + Gem for OS, PFS, and ORR
in the ITT population [17, 18] was also evident in the PET cohort.
Metabolic response rates at week 8 were similar to best meta-
bolic response rates during the study, indicating that PET is a
useful early predictor of the treatment outcome. Determining
that a given treatment is ineffective at an early time point may
allow either optimization of an existing regimen or a switch to a
different, potentially more effective treatment. Thus, sensitive
markers of tumor response are of great value. In the PET cohort
of the MPACT study, the rate of metabolic response by EORTC
criteria at week 8 was substantially higher than the ORR by
RECIST (67% versus 30% for nab-P + Gem and 51% versus 10%
for Gem alone), suggesting that metabolic response by PET may
be the more sensitive measure of tumor response. PET may
more effectively measure subtle changes in tumors. For example,
an effective treatment might induce a necrotic core in the inter-
ior of a large tumor, which would be apparent by PET, but not
necessarily by a CT scan. Although it is beyond the scope of the
current analysis, understanding the association between tumor
biology and likelihood of achieving a metabolic response may
warrant further study.
PET imaging may provide useful information to supplement
radiologic ﬁndings in guiding treatment decisions in pancreatic
cancer. Evaluation of OS based on response by RECIST and
metabolic response by PET at week 8 revealed that patients with
both types of response experienced the longest OS, and patients
with neither type of response had the worst OS. Patients with only
one type of response had similar median OS values; however, 126
patients had a metabolic response only versus 7 patients with a
RECIST response only. The median OS was >3 months longer for
patients with a metabolic response only than for patients who did
not experience a response by either measure, suggesting that meta-
bolic response may predict a degree of treatment beneﬁt, even in the
absence of a tumor response by RECIST (Table 3). Importantly,
this study conﬁrms the overall association of a PET metabolic re-
sponse with OS as observed in the phase I/II study [16].
The metabolic response rate in this study was based primarily
on follow-up scans at week 8 (end of cycle 1) or 16. Whether
metabolic responses might have been observed at an earlier time
point is an interesting question. In gastrointestinal stromal
tumor studies, a metabolic response 4 weeks after the initiation
of therapy was predictive of tumor response [13, 19]; in some
forms of gastric cancer, a metabolic response as early as 2 weeks
into treatment was predictive of the clinical outcome [13, 19].
Recent methods for PET imaging that were optimized for early
prediction of clinical outcomes should be tested to augment the
promising ﬁndings of this study [10, 20].
In summary, patients who achieve a metabolic response
appear to have good clinical outcomes, regardless of treatment.
PET imaging for measuring tumor response in this setting was
feasible early (week 8) and predicted treatment efﬁcacy, includ-
ing longer survival. In addition, the PET response data were
consistent with other efﬁcacy data in MPACT; signiﬁcantly
more patients receiving nab-P + Gem versus Gem alone had a
metabolic response. Patients without a metabolic response re-
ceiving nab-P + Gem had better outcomes than patients without
a metabolic response who received Gem alone. Furthermore, at
week 8, metabolic response by PET was observed in a 5× higher
proportion of patients than RECIST-deﬁned response, indicat-
ing that it may be a more sensitive measure of tumor response
than radiographic modalities. If validated in other studies, its
use may help optimize patient care by allowing a more rapid
identiﬁcation of potentially efﬁcacious treatments and facilitates
in treatment decision.
additional quality assurance metrics
The mean duration of FDG uptake before scanning was 67.4
min at baseline, 68.6 min at week 8, and 67.3 min at week 16.
The mean difference per patient from baseline to week 8 was
1 min (standard deviation = 12.4), and the mean difference from
baseline to week 16 was 0.3 min (standard deviation = 12.5).
statistical methods
Efﬁcacy analyses in the overall population were based on the
ITT population (all randomized patients). The primary end
point was OS, which was deﬁned as the duration from random-
ization in the trial to the time of death. Secondary end points
included PFS, deﬁned as the duration from randomization to
disease progression by RECIST or death, and ORR by independ-
ent evaluation.
OS and PFS were evaluated using Kaplan–Meier methods. OS
and PFS data were censored in cases of ongoing follow-up at
study closure or lost follow-up. PFS data were also censored for
the following reasons: scanning discontinued on disease pro-
gression per investigator, no postbaseline assessment, initiation
of subsequent therapy, or two or more consecutive missing
scans followed by a PFS event.
Analysis of PET ﬁndings was a predeﬁned exploratory end
point; as an exploratory end point, the sample size was not spe-
ciﬁcally planned to allow statistical comparisons of PET data.
All patients enrolled at PET-equipped centers were to be evalu-
ated by PET until a protocol amendment speciﬁed that subse-
quently enrolled patients would not undergo PET imaging due
to logistical constraints and cost considerations. The PET cohort
was deﬁned as the set of patients who received a PET/CT scan at
baseline. Analyses were based on best PET response at week 8 or
16 (±2 weeks) or best PET response throughout treatment.
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SAS version 9.1 software was used for all statistical compari-
sons. All P values were two-sided, and a P value of <0.05 was
considered statistically signiﬁcant.
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